Syngene International Ltd management interview: Syngene International Q2: Profit Falls 52%, So Why Is The Stock Rising? | Business News | ET Now
ET Now, 2026-10-28. Video: https://www.youtube.com/watch?v=ogjQDIfhpqI
- Quarterly performance: Revenue grew 13% sequentially, mainly from CDMO, but declined 8% year on year due to the absence of Librela sales in Q2 and some weakness in Discovery. Other CDMO business grew.
- Margin trajectory: Margins improved sequentially despite forex hedge losses; excluding those losses, EBITDA was almost in the mid-20s. Syngene guided to mid-20s margins for fiscal 27, with hedge losses expected to continue through FY 28.
- Second-half outlook: Management expects H2 to be stronger than H1, citing customer obligations, a growing sales pipeline and conversions into business.
- Bayview facility: Syngene has signed its first contract, with development work beginning in Bangalore and filing batches planned for next fiscal year. Management gave no near-term revenue guidance, but said the facility offers customers a US-India dual-site advantage and should help attract more large-molecule CDMO customers.
- Business mix: Discovery currently contributes 65% of revenue and CDMO 35%; CDMO is expected to become a larger contributor over time and drive short- to mid-term growth, while Discovery remains a core business line.